Literature DB >> 28867981

Review of Regorafenib for the Treatment of Hepatocellular Carcinoma.

Richard S Finn1.   

Abstract

Entities:  

Year:  2017        PMID： 28867981      PMCID： PMC5572963     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  4 in total

Review 1.  Systemic therapy for advanced hepatocellular carcinoma: an update.

Authors:  Jasmin Radhika Desai; Sebastian Ochoa; Petra Alexandra Prins; Aiwu Ruth He
Journal:  J Gastrointest Oncol       Date:  2017-04

Review 2.  New chemical treatment options in second-line hepatocellular carcinoma: what to do when sorafenib fails?

Authors:  Hyun Young Woo; So Young Yoo; Jeong Heo
Journal:  Expert Opin Pharmacother       Date:  2016-11-28       Impact factor: 3.889

Review 3.  Regorafenib for the treatment of unresectable hepatocellular carcinoma.

Authors:  Lorenza Rimassa; Tiziana Pressiani; Nicola Personeni; Armando Santoro
Journal:  Expert Rev Anticancer Ther       Date:  2017-06-09       Impact factor: 4.512

4.  Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Jordi Bruix; Shukui Qin; Philippe Merle; Alessandro Granito; Yi-Hsiang Huang; György Bodoky; Marc Pracht; Osamu Yokosuka; Olivier Rosmorduc; Valeriy Breder; René Gerolami; Gianluca Masi; Paul J Ross; Tianqiang Song; Jean-Pierre Bronowicki; Isabelle Ollivier-Hourmand; Masatoshi Kudo; Ann-Lii Cheng; Josep M Llovet; Richard S Finn; Marie-Aude LeBerre; Annette Baumhauer; Gerold Meinhardt; Guohong Han
Journal:  Lancet       Date:  2016-12-06       Impact factor: 79.321
  4 in total
  1 in total

Review 1.  The Role of IGF/IGF-1R Signaling in Hepatocellular Carcinomas: Stemness-Related Properties and Drug Resistance.

Authors:  Mai-Huong Thi Ngo; Han-Yin Jeng; Yung-Che Kuo; Josephine Diony Nanda; Ageng Brahmadhi; Thai-Yen Ling; Te-Sheng Chang; Yen-Hua Huang
Journal:  Int J Mol Sci       Date:  2021-02-16       Impact factor: 5.923
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.